CA2065346A1 - Tumor necrosis factor-.alpha. and-.beta. receptors - Google Patents

Tumor necrosis factor-.alpha. and-.beta. receptors

Info

Publication number
CA2065346A1
CA2065346A1 CA002065346A CA2065346A CA2065346A1 CA 2065346 A1 CA2065346 A1 CA 2065346A1 CA 002065346 A CA002065346 A CA 002065346A CA 2065346 A CA2065346 A CA 2065346A CA 2065346 A1 CA2065346 A1 CA 2065346A1
Authority
CA
Canada
Prior art keywords
necrosis factor
tumor necrosis
receptors
beta
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002065346A
Other languages
French (fr)
Other versions
CA2065346C (en
Inventor
Craig A. Smith
Raymond G. Goodwin
M. Patricia Beckmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002485553A priority Critical patent/CA2485553A1/en
Publication of CA2065346A1 publication Critical patent/CA2065346A1/en
Application granted granted Critical
Publication of CA2065346C publication Critical patent/CA2065346C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Tumor necrosis factor receptor proteins, DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.
CA002065346A 1989-09-05 1990-07-17 Tumor necrosis factor-.alpha. and-.beta. receptors Expired - Lifetime CA2065346C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002485553A CA2485553A1 (en) 1989-09-05 1990-07-17 Tumor necrosis factor - .alpha. and - .beta. receptors

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US405,370 1982-08-05
US40324189A 1989-09-05 1989-09-05
US403,241 1989-09-05
US40537089A 1989-09-11 1989-09-11
US42141789A 1989-10-13 1989-10-13
US421,417 1989-10-13
PCT/US1990/004001 WO1991003553A1 (en) 1989-09-05 1990-07-17 TUMOR NECROSIS FACTOR-α AND -β RECEPTORS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002485553A Division CA2485553A1 (en) 1989-09-05 1990-07-17 Tumor necrosis factor - .alpha. and - .beta. receptors

Publications (2)

Publication Number Publication Date
CA2065346A1 true CA2065346A1 (en) 1991-03-06
CA2065346C CA2065346C (en) 2005-03-29

Family

ID=46201946

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002065346A Expired - Lifetime CA2065346C (en) 1989-09-05 1990-07-17 Tumor necrosis factor-.alpha. and-.beta. receptors
CA002485553A Expired - Lifetime CA2485553A1 (en) 1989-09-05 1990-07-17 Tumor necrosis factor - .alpha. and - .beta. receptors

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002485553A Expired - Lifetime CA2485553A1 (en) 1989-09-05 1990-07-17 Tumor necrosis factor - .alpha. and - .beta. receptors

Country Status (3)

Country Link
AU (1) AU630497B2 (en)
CA (2) CA2065346C (en)
WO (1) WO1991003553A1 (en)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2238070T3 (en) 1989-04-21 2005-08-16 Amgen Inc. TNF RECEPTOR, TNF BINDING PROTEIN AND CODANT DNA FOR THESE.
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
ATE194384T1 (en) 1989-09-12 2000-07-15 Hoffmann La Roche TNF-BINDING PROTEINS
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
JPH06508502A (en) * 1991-03-29 1994-09-29 イミュネックス・コーポレーション isolated viral protein cytokine antagonist
WO1993006128A1 (en) * 1991-09-16 1993-04-01 Peptide Technology Limited Tnf antagonist peptides
JP3122139B2 (en) * 1991-10-15 2001-01-09 マラーキー，ミッシェル，エフ． Composition for treating late stage inflammatory response
WO1994006476A1 (en) * 1992-09-15 1994-03-31 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
WO1994021282A1 (en) * 1993-03-19 1994-09-29 Immunex Corporation Pharmaceutical compositions comprising a ligand complexed with a soluble receptor
NZ278607A (en) * 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
CA2244664C (en) 1996-02-09 2008-06-03 Amgen Inc. Composition comprising interleukin-1 inhibitor and controlled release polymer
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
EP0949931B1 (en) 1996-12-06 2008-08-27 Amgen Inc., Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
JP2001513754A (en) 1996-12-06 2001-09-04 アムジェン インコーポレイテッド Combination therapy using TNF binding proteins for treating TNF-mediated diseases
US6893838B1 (en) 1998-04-07 2005-05-17 Genetics Institute Llc DADD, death activator death domain protein
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7041474B2 (en) * 1998-12-30 2006-05-09 Millennium Pharmaceuticals, Inc. Nucleic acid encoding human tango 509
US20080213778A1 (en) 1998-12-30 2008-09-04 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
EP1176194B1 (en) * 1999-05-10 2005-07-20 Chugai Seiyaku Kabushiki Kaisha Method of cell cultivation
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
ES2382891T3 (en) 2000-05-26 2012-06-14 Immunex Corporation Use of IL-4R antibodies and their compositions
SG10201603108QA (en) 2001-06-26 2016-05-30 Amgen Inc Antibodies To OPGL
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
DK1944322T3 (en) 2002-07-19 2015-06-22 Abbvie Biotechnology Ltd Treatment of TNFalfa-related diseases
TWI556829B (en) 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 Multiple variable dose therapy for the treatment of TNFα-related disorders
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
KR20130086254A (en) 2005-05-16 2013-07-31 애브비 바이오테크놀로지 리미티드 Use of tnf inhibitor for treatment of erosive polyarthritis
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
CA2626804A1 (en) 2005-11-01 2007-08-09 Abbott Biotechnology Ltd. Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
EP2703010A3 (en) 2006-04-10 2014-08-06 AbbVie Biotechnology Ltd Uses and compositions for treatment of rheumatoid arthritis
CA2564435A1 (en) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methods for monitoring and treating intestinal disorders
EP2007426A4 (en) 2006-04-10 2010-06-16 Abbott Biotech Ltd Uses and compositions for treatment of psoriatic arthritis
BRPI0713802A2 (en) 2006-06-30 2012-11-06 Abbott Biotech Ltd automatic injection device
WO2008025748A1 (en) 2006-08-28 2008-03-06 Ares Trading S.A. Process for the purification of fc-containing proteins
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
EP2679995A1 (en) 2007-05-31 2014-01-01 AbbVie Inc. Biomarkers predictive of the responsiveness to TNF-alfa inhibitors in autoimmune disorders
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd Methods for treating juvenile idiopathic arthritis
EP2384367A4 (en) 2008-12-30 2013-07-10 Janssen Biotech Inc Serum markers predicting clinical response to anti-tnf antibodies in patients with ankylosing spondylitis
CN102458517B (en) 2009-04-29 2014-07-23 阿布维生物技术有限公司 Automatic injection device
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
WO2011075578A1 (en) 2009-12-16 2011-06-23 Philip Bosch Methods of treating interstitial cystitis
US8883151B2 (en) 2010-01-15 2014-11-11 Kirin-Amgen, Inc. IL-17 receptor antibody formulation
EP2531613A2 (en) 2010-02-02 2012-12-12 Abbott Biotechnology Ltd. Methods and compositions for predicting responsiveness to treatment with tnf-alpha inhibitor
WO2011133823A1 (en) 2010-04-21 2011-10-27 Abbott Biotechnology Ltd. Wearable automatic injection device for controlled delivery of therapeutic agents
US20110287018A1 (en) 2010-05-19 2011-11-24 Philip Bosch Methods of Treating Interstitial Cystitis
PL2575884T3 (en) 2010-06-03 2018-12-31 Abbvie Biotechnology Ltd Uses and compositions for treatment of hidradenitis suppurativa (hs)
EP2490024A1 (en) 2010-12-22 2012-08-22 Proteomika, S.L. Method to optimize the treatment of patients with biological drugs
AU2012209223B2 (en) 2011-01-24 2015-11-05 Abbvie Biotechnology Ltd Automatic injection devices having overmolded gripping surfaces
BR112013023967A2 (en) 2011-03-18 2016-01-19 Abbvie Inc systems, devices and methods for assembling automatic injection devices and subsets thereof
CA2831563A1 (en) 2011-03-29 2012-10-04 Abbvie Inc. Improved shroud deployment in automatic injection devices
EP2699286B1 (en) 2011-04-21 2016-08-31 AbbVie Inc. Wearable automatic injection device
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
JP2016511747A (en) * 2013-01-04 2016-04-21 マサチューセッツ インスティテュート オブ テクノロジー Drug delivery to tissues based on nanoparticle surface binding
US20170174772A1 (en) 2014-03-31 2017-06-22 Kirin-Amgen, Inc. Methods of treating nail and scalp psoriasis
WO2016102328A1 (en) 2014-12-22 2016-06-30 Ares Trading S.A. Liquid pharmaceutical composition
AU2017248354A1 (en) 2016-04-08 2018-10-04 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
US20180193003A1 (en) 2016-12-07 2018-07-12 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112240A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
JOP20190162A1 (en) 2016-12-30 2019-06-27 Biocad Joint Stock Co Aqueous Pharmaceutical Composition of a Recombinant Monoclonal Antibody to TNF?
WO2019246313A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
CA3103664A1 (en) 2018-07-03 2020-01-09 Novartis Ag Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist
JP2022505562A (en) 2018-10-24 2022-01-14 ノバルティス アーゲー Compounds and compositions for treating conditions associated with NLRP activity
EP3880673B1 (en) 2018-11-13 2024-01-03 Novartis AG Compounds and compositions for treating conditions associated with nlrp activity
CN113166081A (en) 2018-11-13 2021-07-23 诺华股份有限公司 Compounds and compositions for treating conditions associated with NLRP activity
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
EP3914583A1 (en) 2019-01-22 2021-12-01 Novartis AG Compounds and compositions for treating conditions associated with nlrp activity
WO2021002887A1 (en) 2019-07-02 2021-01-07 Novartis Inflammasome Research, Inc. Gut-targeted nlrp3 antagonists and their use in therapy
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
IL319437A (en) 2022-09-07 2025-05-01 Mdx Man Llc SHP-1 inhibitors for cancer treatment
WO2024097804A1 (en) 2022-11-02 2024-05-10 Mdx Management Llc Combination of a tyrosine kinase inhibitor and a pro-inflammatory agent for treating cancer
WO2024196822A1 (en) 2023-03-17 2024-09-26 Mdx Management Llc Compositions and methods for ameliorating adverse effects of therapies
WO2025038745A1 (en) 2023-08-16 2025-02-20 Mdx Management Llc Compositions and methods for activating immune cells
WO2025049345A1 (en) 2023-08-25 2025-03-06 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
GB8806339D0 (en) * 1988-03-17 1988-04-13 Hoffmann La Roche Monoclonal antibodies
GB8807803D0 (en) * 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product

Also Published As

Publication number Publication date
CA2065346C (en) 2005-03-29
WO1991003553A1 (en) 1991-03-21
AU630497B2 (en) 1992-10-29
CA2485553A1 (en) 1991-03-21
AU6178190A (en) 1991-04-08

Similar Documents

Publication Publication Date Title
CA2065346A1 (en) Tumor necrosis factor-.alpha. and-.beta. receptors
GR3019333T3 (en) Tumor necrosis factor-alpha and -beta receptors
EP0318296A3 (en) Interleukin-1 receptors
IL98205A0 (en) Type ii interleukin-1 receptors
WO1998030694A3 (en) TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
CA2032191A1 (en) Expression of the recombinant tumor necrosis factor binding protein i (tbp-i)
CA2267670A1 (en) Method for preparing human stem cell factor polypeptide
KR19980701570A (en)
IL83192A0 (en) Method for the preparation of proteins with factor viii activity by microbial host cells;expression vectors,host cells,antibodies
AU9482498A (en) Interleukin-17 receptor-like protein
IL91705A0 (en) Interleukin-4 receptors,dna and expression vectors encoding them and process for producing the receptors
CA2108473A1 (en) Heregulins (hrgs) binding proteins of p185erb2
IE902158L (en) Interleukin-7 Receptors
IL88151A (en) Interleukin-7 protein, dna sequences encoding it, its preparation and compositions containing it
IL87622A0 (en) Recombinant eukaryotic cells producing interleukin-2,process and vectors for their preparation and process for the preparation of interleukin-2
IL84700A (en) Hybrid proteins,dnas coding therefor,hybrid vectors containing such dnas and hosts transformed therewith,the preparation of such hybrid proteins and pharmaceutical compositions containing them
GB2171703B (en) Expression-secretion vector for gene expression and protein secretion, recombinant dna including the vector, and method of producing proteins by use of the re
CA2051010A1 (en) Human luteinizing hormone-chorionic gonadotropin receptor protein, dna and use thereof
DK0494260T3 (en) Receptors for granulocyte colony stimulating factor
CA2089111A1 (en) Smooth muscle mitogen and isolated dna coding therefor
ZA875267B (en) Method for the preparation of proteins with factor viii activity by microbial host cells;expression vectors,host cells,antibodies

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry